BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Post by Time4TAon May 26, 2011 10:38am

242 Views

Post# 18628239

Sector Rotation - > Biotech Back in Play

WHen the Money Flows out of Commodities - Biotech will benefit Greatly. Loading Up here before the Market Switches Over...Early Birds Get Rewarded as always. Time to BUY BLU....
Nice Chart....Weak Hands all Squeezed out....Big Accumulation was don at Much Higher Levels....Screaming BUY as of May 26, 2011. Target
.125 by Next Month